In light of these considerations, Zelin updated BTIG's model to reflect a more moderate differentiation of briquilimab versus barzolvolimab and the decreased likelihood of a Q12W regimen. Despite the price target reduction, BTIG reiterated its Buy rating, citing upcoming catalysts that could positively impact Jasper Therapeutics. These include the expectation of updated BEACON study data in the second half of 2025 and initial asthma data anticipated within the same timeframe.
With a market capitalization of $107 million and an overall Financial Health score of FAIR according to InvestingPro, investors should monitor the company's progress closely.Access the complete JSPR Pro Research Report and discover what really matters about this stock through intuitive visuals and expert analysis, available exclusively on InvestingPro.
With a market capitalization of $107 million and an overall Financial Health score of FAIR according to InvestingPro, investors should monitor the company's progress closely.Access the complete JSPR Pro Research Report and discover what really matters about this stock through intuitive visuals and expert analysis, available exclusively on InvestingPro.
In light of these considerations, Zelin updated BTIG's model to reflect a more moderate differentiation of briquilimab versus barzolvolimab and the decreased likelihood of a Q12W regimen. Despite the price target reduction, BTIG reiterated its Buy rating, citing upcoming catalysts that could positively impact Jasper Therapeutics. These include the expectation of updated BEACON study data in the second half of 2025 and initial asthma data anticipated within the same timeframe.
With a market capitalization of $107 million and an overall Financial Health score of FAIR according to InvestingPro, investors should monitor the company's progress closely.Access the complete JSPR Pro Research Report and discover what really matters about this stock through intuitive visuals and expert analysis, available exclusively on InvestingPro.
The BEACON study's 240mg dosage yielded a placebo-adjusted UAS7 (Urticaria Activity Score over 7 days) of 14.2, surpassing expectations and bolstering the case for advancing the every eight weeks (Q8W) regimen to a registrational study, contingent on ongoing favorable safety outcomes.
Nonetheless, questions linger regarding the safety of the 240mg dose, as detailed safety tables by dose level were not disclosed. Concerns also exist about the small sample size of n=3 and the potential for the company to explore a 360mg every twelve weeks (Q12W) regimen in the future.
In light of these considerations, Zelin updated BTIG's model to reflect a more moderate differentiation of briquilimab versus barzolvolimab and the decreased likelihood of a Q12W regimen. Despite the price target reduction, BTIG reiterated its Buy rating, citing upcoming catalysts that could positively impact Jasper Therapeutics. These include the expectation of updated BEACON study data in the second half of 2025 and initial asthma data anticipated within the same timeframe.
In other recent news, Jasper Therapeutics has been in the spotlight due to several developments. The company reported preliminary data from the BEACON trial that showed a perplexing dose-response relationship for its lead therapeutic candidate, briquilimab. The study observed significant improvements in disease symptoms with a favorable safety profile. Despite these positive results, Jasper's stock experienced a sharp decline, suggesting investor concerns or unmet expectations.
Analysts from various firms including Stifel, Oppenheimer, BMO Capital Markets, H.C. Wainwright, and BTIG have maintained positive ratings on Jasper Therapeutics. The analysts are particularly keen on the UAS7 (Urticaria Activity Score over 7 days) results at week 12, as well as the preliminary safety profile of briquilimab.
Jasper Therapeutics plans to initiate a registrational CSU program in the second half of 2025 and aims to expand the BEACON trial to gather additional supporting data. The company has also received clearance from Health Canada to commence a Phase 1b/2a clinical trial for briquilimab as a potential treatment for asthma.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.